Skip to content

Trial Summary

This 2-part study will evaluate the safety and efficacy of pembrolizumab (MK-3475) compared to placebo in participants with surgically resected high-risk Stage II melanoma.



ACTRN/NCT /ethics:


Scientific title:

Safety and efficacy of pembrolizumab compared to placebo in resected high-risk stage II melanoma

Sponsor / Cooperative group:

Merck Sharp & Dohme Corp.

Trial & Patient Characteristics

Cancer TypeMelanoma & other skin
Trial TypeTreatment
PhasePhase III
Age Range12 years and older
Tumour Stream -
Cancer StageAll stages
Anticipated Start Date2018-09-12
Anticipated End Date2033-10-21

Participating Hospitals

HospitalRoyal Adelaide Hospital
Clinical Trial CoordinatorAnne Milton
Phone08 7074 2342
Principal InvestigatorProfessor Michael Brown
Recruitment StatusRecruiting
HospitalAshford Cancer Centre Research
Clinical Trial CoordinatorSue Yeend
Phone08 8292 2240
Principal InvestigatorDr Brian Stein
Recruitment StatusRecruiting